Q2 2027 STERIS plc Earnings Conference Call - STERIS PLC

Explicit Guidance:

• FY2027 Revenue: Maintained as-reported revenue growth of 7% to 8% and constant currency organic growth of 6% to 7%.
• FY2027 Earnings: Increased adjusted earnings per diluted share (EPS) outlook to $1.35–$1.55 (up from prior $1.10–$1.30 range), including $0.18/share benefit from tariff refunds.
• Segment Revenue Growth (FY2027):
  • Healthcare: Constant currency organic growth of 6% to 7%.
  • Applied Sterilization Technologies (AST): Revised down to constant currency organic growth of 6% to 7% (from 7%–8%).
  • Life Sciences: Revised up to constant currency organic growth of 9% to 10% (from 6%–7%), driven by capital equipment normalization.
• Acquisition (Exodus Medical): Excludes acquisition from current FY2027 guidance; updated expectations provided post-close.
• Restructuring Charges: Anticipates total charges of $45 million (including $10 million cash, $35 million non-cash), with $25 million already recorded in Q2.

Business-Segment Outlook:

• Healthcare:
  • GI Business: Driven by procedural growth and share gains; endoscopy consumption and machine placements remain strong.
  • Capital Equipment: Orders stable; backlog increased to $456 million; expected to benefit from patient acuity shifts to acute care facilities and 340B reform stability.
  • Margins: Underlying margins pressure due to inflation and R&D acceleration, partially offset by price/volume.
• AST (Applied Sterilization Technologies):
  • Volume/Demand: Destocking phase declared complete; Q2 Q3/Q4 transitioned to normalized growth; October/November showing strong performance.
  • Margins: Leverage expected as volumes return to existing infrastructure, offset slightly by new facilities in ramp-up and dilutive depreciation.
  • Utilization: Network utilization high with adequate capacity on existing infrastructure; no need for immediate new capacity installation.
• Life Sciences:
  • Growth Drivers: Reshoring, localization of manufacturing, and catch-up from prior underbuying; record EBIT margin of 44.4%.
  • Backlog: Ended quarter at $93 million.
  • Future Tech: "Self-driving labs" identified as a long-term opportunity, though not yet reflected in order book.
• Acquisition (Exodus Medical):
  • Growth: Expected to maintain mid-teens revenue growth.
  • Margins: Expected EBIT margins in low-to-mid 50s.
  • Strategic Fit: Adds high-margin consumables, recurring revenue, and a direct clinical sales force in operating rooms.
• Restructuring Impact: Plan targets facility realignment, product rationalization (e.g., discontinuing single-use urology scope), and site consolidation (shifting sterility assurance to Mentor site). Expected to generate $9 million annualized savings, with partial realization in FY2028 and full benefit in subsequent years.

Market and Competitive Outlook:

• Procedure Volumes: Expect US procedural growth at the low end of the range (~3%); high elective procedures may face deferral, but overall demand remains positive with up-tray consumption.
• Share Gains: Healthcare consumables growth supported by installed base of chemistry equipment (BPROs, AERs) converting to consumables; minor share gains from competitor (Olympus) challenges but not a primary driver.
• Pricing: Favorable pricing trends offsetting inflation in several segments; price increases utilized to manage margin expansion.
• Competitive Environment: Viewed as stable; AST growth supported by strong comps in H2 2026 vs. H1 2026.

Macro / Industry Outlook:

• Tariffs: No material additional tariff refunds expected for remainder of FY2027; total expected pool of refunds is $24 million (approx. $3 million of paid tariffs ineligible for refund).
• Interest Rates: Lower interest rates cited as a driver for EPS guidance increase; deal financing assumed at ~6% interest rate.
• Geopolitics/Regulation: US 340B reform finalized; management sees no material impact on CapEx outlook.
• Demand Trends: "Reshoring" and "localization" of manufacturing actively benefiting Life Sciences segment; destocking in AST concluded.

Strategic Initiatives:

• M&A: Acquisition of Exodus Medical (surgical specialties/patient safety products) announced; expected to be EPS accretive (estimated 3–5% annual accretion) upon close, subject to debt financing costs.
• Restructuring: Two plans executed in current fiscal year (August and Q2); focus on portfolio challenge, manufacturing network optimization, and distribution efficiency.
• Investment: Acceleration of R&D spending and capital investments to support long-term growth.
• Capacity: Maintenance of isotope loading rates to capture future volume; ramp-up of new facilities contributing to near-term margin dilution.

Risks and Headwinds to Outlook:

• Inflation: Ongoing inflationary pressures on costs offsetting price/volume gains in healthcare margins.
• Macro Uncertainty: Economic stress for customers, particularly in North America, could impact elective procedure volumes.
• One-Time Items: Single $10M+ Life Sciences order in Q2 not expected to repeat quarterly; margin improvements in Q2 heavily reliant on one-time tariff refunds.
• Acquisition Integration: Final EPS impact contingent on closing timing and interest cost assumptions.
• Regulatory/Product Specifics: Potential deferral of highly elective procedures; inventory disposal and intangible impairments associated with restructuring.

Management Tone on the Future:

• Confidence: High confidence in H2 2026 performance relative to easier comps; view on AST recovery is decisive ("destocking has ended").
• Strategic Direction: Aggressive focus on portfolio optimization and manufacturing efficiency (three restructuring plans in short timeframe).
• Hedges: Explicitly excludes acquisition impact from current guidance; notes that "self-driving labs" are an opportunity not yet quantifiable in orders.

Miscellaneous:

• Share Buybacks: $100 million spent in Q2; $800 million authorization remaining (total YTD spend $200 million).
• Balance Sheet: Gross debt of $1.9 billion; Gross debt to EBITDA at ~1.1x.
• Cash Flow: Free cash flow $492.5M (H1); build in inventory for H2 shipments reduced Q1/Q2 working capital contribution.
• Tax Rate: Adjusted effective tax rate 25.3% (elevated due to unfavorable discrete items); outlook assumes unchanged.